Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein (MALS & SPR verified), Unconjugated

Product Overview

• Article Name: Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein (MALS & SPR verified), Unconjugated
• Biozol Catalog Number: ABS-HL1-H52E8-200UG
• Supplier Catalog Number: HL1-H52E8-200ug
• Alternative Catalog Number: ABS-HL1-H52E8-200UG
• Manufacturer: AcroBiosystems
• Host: Human
• Category: Proteine/Peptide
• Species Reactivity: Human
• Conjugation: Unconjugated

Product Description

NYESO1, which is also wellknown as New York esophageal squamous cell carcinoma 1, is an efficient target for cancer immunotherapy. This antigen is a member of cancertestis antigens (CTAs) and is highly expressed in various cancers, including melanoma, ovarian, cervical cancer, etc. Adoptive T cell therapy with HLAA2 restricted NYESO1 transduced CD8+ T cells has improved the clinical response rates and overall survival of treatmentrefractory melanoma patients. The Human HLAA*0201 NYESO1 (SLLMWITQC) complex protein is a complex of HLAA*0201 of the MHC Class I, B2M and SLLMWITQC peptide of the NYESO1. - Proteine/Peptide

Product Properties

• Molecular Weight: 36.3 kDa, 13.8 kDa and 13.3 kDa
• Tag: C-10*His
• NCBI: 59606
• Buffer: PBS, pH7.4
• Expression System: Gly 25 - Ile 308 (HLA-A*02:01) & Ile 21 - Met 119 (B2M) & SLLMWITQC peptide
• Purity: 90%
• Form: Powder
• Target: HLA-A*02:01 & B2M & NY-ESO-1 (SLLMWITQC)

Images

HL1-H52E8-200ug